BIOXYTRAN INC (BIXT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BIXT SEC filings page.
This page shows BIOXYTRAN INC (BIXT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The business remains expense-funded, with no reported revenue, negative equity, and financing inflows carrying more weight than operations.
In FY2025, the net loss of$2.1M was much larger than operating cash outflow of$526K , indicating that noncash items or timing effects materially shaped the reported loss. Because financing supplied$1.1M while operations consumed cash, funding—not operating receipts—was the immediate source of cash movement.
At FY2025, liabilities exceeded assets by roughly five times:
The 0.2x current ratio shows that current assets were only a small fraction of current liabilities, creating a pronounced short-term funding mismatch. The reported liquidity comparison was 11.6 months of the latest annual operating outflow, but that figure does not change the underlying dependence on external financing visible in the cash-flow data.
Financial Health Signals
BIOXYTRAN INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
BIOXYTRAN INC passes 2 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 3 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
BIOXYTRAN INC reported a net loss of $2.1M while operations used $526K of cash. With neither figure positive, the ratio between the two carries no quality signal.
BIOXYTRAN INC reported an operating loss of $1.8M against $134K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
BIOXYTRAN INC reported -$620K in net income in Q2 2026. This represents a decrease of 1849.3% from the same quarter a year earlier. Against the prior quarter it is up 70.0%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
BIOXYTRAN INC held $177K in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
None of these metrics is reported for Q2 2026.
Capital Allocation
BIOXYTRAN INC invested $255K in research and development in Q2 2026. This represents an increase of 149.2% from the same quarter a year earlier. Against the prior quarter it is up 13.3%.
Not reported for Q2 2026.
Not reported for Q2 2026.
BIXT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $255K+149.2% | $225K-35.5% | N/A | N/A | $103K | $350K+1194.4% | N/A | $51K-83.9% |
| SG&A Expenses | $189K+100.1% | $214K+48.8% | N/A | $159K+0.7% | $95K-78.9% | $144K-55.2% | N/A | $158K-32.1% |
| Operating Income | -$655K-192.1% | -$1.9M-275.2% | N/A | -$496K-43.3% | -$224K+63.2% | -$515K | N/A | -$346K |
| Interest Expense | $36K+20.0% | $36K+14.7% | N/A | $37K+104.7% | $30K+52.6% | $31K+18.1% | N/A | $18K-63.4% |
| Net Income | -$620K-1849.3% | -$2.1M | N/A | -$283K+27.9% | $35K | N/A | N/A | -$392K |
| EPS (Basic) | -$0.01 | -$0.020.0% | $0.00+100.0% | $0.00 | $0.00 | -$0.02 | -$0.01 | $0.00+100.0% |
| EPS (Diluted) | -$0.01 | -$0.020.0% | $0.00+100.0% | $0.00 | $0.00 | -$0.02 | -$0.01 | $0.00+100.0% |
| Diluted Shares (Avg) | 114M+28.7% | 112M+26.4% | N/A | 89M-29.6% | 89M | 89M | N/A | 126M-7.4% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, EBITDA, Income Tax.
BIXT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $333K+126.0% | $615K+352.2% | $659K+374.8% | $156K-1.7% | $148K+14.7% | $136K+8.4% | $139K-0.5% | $159K-15.9% |
| Current Assets | $177K+5542.0% | $463K+10549.7% | $513K+9862.5% | $14K-58.2% | $3K-76.7% | $4K-56.6% | $5K-80.2% | $35K-56.8% |
| Cash & Equivalents | $177K+5542.0% | $463K+10549.7% | $510K+9793.6% | $14K-58.2% | $3K-76.7% | $4K-56.6% | $5K-80.2% | $35K-56.8% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $5.3M+89.5% | $5.0M+76.2% | $3.2M+68.3% | $3.1M+146.1% | $2.8M+126.5% | $2.8M+154.9% | $1.9M-40.5% | $1.2M-46.7% |
| Current Liabilities | $5.3M+89.5% | $5.0M+76.2% | $3.2M+68.3% | $3.1M+146.1% | $2.8M+126.5% | $2.8M+154.9% | $1.9M-40.5% | $1.2M-46.7% |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0-100.0% |
| Total Equity | -$4.9M-87.5% | -$4.4M-62.3% | -$2.6M-44.6% | -$2.9M-167.8% | -$2.6M-139.6% | -$2.7M-173.4% | -$1.8M+42.3% | -$1.1M+49.4% |
| Retained Earnings | -$23.7M-17.3% | -$23.1M-14.0% | -$21.0M-11.2% | -$20.5M-12.1% | -$20.2M-19.3% | -$20.3M-24.4% | -$18.9M-20.5% | -$18.3M-25.8% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
BIXT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$350K-377.9% | -$239K-42.6% | -$237K-85.2% | -$49K+33.4% | -$73K-4.2% | -$167K-52.7% | -$128K-38.1% | -$74K+78.5% |
| Stock-Based Compensation | N/A | $1.3M+4678.2% | N/A | N/A | N/A | $27K-84.0% | N/A | $8K-89.7% |
| Investing Cash Flow | -$9K+25.8% | -$9K-61413.3% | -$6K+48.3% | -$4K+61.3% | -$13K-1925.8% | -$15+99.7% | -$12K-84.0% | -$11K+14.7% |
| Financing Cash Flow | $73K-13.2% | $201K+20.7% | $739K+568.5% | $65K-38.9% | $85K+15.8% | $167K+67.4% | $110K+145.5% | $106K-73.0% |
Not reported in any period shown, so not listed: Depreciation & Amortization, Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
BIXT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Debt-to-Equity, Asset Turnover, FCF Margin.
Note: Shareholder equity is negative (-$2.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.16), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BIOXYTRAN INC BIXT | FY2025 | N/A | -$2.1M | N/A | $2.6M | — |
| INHIBITOR THERAPTICS INC INTI | FY2025 | N/A | -$3.3M | N/A | $10.3M | — |
| BETTERLIFE PHARMA INC BETRF | FY2018 | N/A | -$121K | N/A | $114.3M | — |
Where BIOXYTRAN INC Ranks
Frequently Asked Questions
Is BIOXYTRAN INC profitable?
No, BIOXYTRAN INC (BIXT) reported a net income of -$2.1M in fiscal year 2025.
What is BIOXYTRAN INC's operating cash flow?
BIOXYTRAN INC (BIXT) recorded an outflow of $526K in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are BIOXYTRAN INC's total assets?
BIOXYTRAN INC (BIXT) had $659K in total assets as of fiscal year 2025, including both current and long-term assets.
How much does BIOXYTRAN INC spend on research and development?
BIOXYTRAN INC (BIXT) invested $454K in research and development during fiscal year 2025.
What is BIOXYTRAN INC's current ratio?
BIOXYTRAN INC (BIXT) had a current ratio of 0.16 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is BIOXYTRAN INC's return on assets (ROA)?
BIOXYTRAN INC (BIXT) had a return on assets of -322.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is BIOXYTRAN INC's P/E ratio?
BIOXYTRAN INC (BIXT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $2.6M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BIOXYTRAN INC's price-to-sales ratio?
BIOXYTRAN INC (BIXT) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $2.6M as of Oct 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does BIOXYTRAN INC's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, BIOXYTRAN INC (BIXT) held $510K in cash, cash equivalents and investments, and reported an operating cash outflow of $526K over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is BIOXYTRAN INC's debt-to-equity ratio negative or not reported?
BIOXYTRAN INC (BIXT) has negative shareholder equity of -$2.6M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is BIOXYTRAN INC's Piotroski F-Score?
BIOXYTRAN INC (BIXT) has a Piotroski F-Score of 2 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BIOXYTRAN INC's earnings high quality?
BIOXYTRAN INC (BIXT) reported a net loss of $2.1M while operations used $526K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BIOXYTRAN INC cover its interest payments?
BIOXYTRAN INC (BIXT) reported an operating loss of $1.8M against $134K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.